In the face of the financial environment in which health facilities currently are evolving, it is now clear and shared that only through a good organization of the surgical event it is possible to achieve significant improvements in quality of care. In this way the economic impact becomes inversely proportional because the establish oneself of the virtuous circle that leads (or at least should lead) to a adequate request of resources that are used in a so much appropriate way to obtain the most practical benefit that ultimately produces case-mixes with high profitability, a good level of quality perceived as high and expenses pragmatically supported by the revenues.

INTRODUCTION

In face to the financial environment in which health facilities currently are evolving, it is now clear and shared that only through a good organization of the surgical event it is possible to achieve significant improvements in quality of care. In this way the economic impact becomes inversely proportional because the establish oneself of the virtuous circle that leads (or at least should lead) to a adequate request of resources that are used in a so much appropriate way to obtain the most practical benefit that ultimately produces case-mixes with high profitability, a good level of quality perceived as high and expenses pragmatically supported by the revenues.

METHODS

The primary endpoint of this study aims to assess, starting from the costs that the information analyzed allow to accurately calculate, the increased efficiency achieved by the availability to the anesthesiologist of sugammadex rather than its unavailability. Moreover, the secondary endpoint aims to formulate organizational scenarios to permit the unlimited use of sugammadex rather than have availability of it in a controlled amount for use based on a protocol. Furthermore, it tries to identify the surgical specialties in which each of the two scenarios can be applied with the highest profit.

ENDPOINTS

The primary endpoint of this study aims to assess, starting from the costs that the information analyzed allow to accurately calculate, the increased efficiency achieved by the availability to the anesthesiologist of sugammadex rather than its unavailability. Moreover, the secondary endpoint aims to formulate organizational scenarios to permit the unlimited use of sugammadex rather than have availability of it in a controlled amount for use based on a protocol. Furthermore, it tries to identify the surgical specialties in which each of the two scenarios can be applied with the highest profit.

DISCLOSURES:
Ronco Gian Luca - Grant Support: MSD Italy.

A methodology for cost / benefit analysis in comparison to the routine choice for reversal.
Ronco Gian Luca, Emmonos S.A.